A Phase 1 interventional study of ATX-101 in Characteristics of Subcutaneous Fat, sponsored by Kythera Biopharmaceuticals. Completed at 2 sites in United States. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-01-27.
Sponsored by Kythera Biopharmaceuticals (part of AbbVie) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Histopathological study of abdominal fat excised from subjects undergoing abdominoplasty
Kythera Biopharmaceuticals is the lead sponsor of 23 studies on the registry; none are open to participants now.
First submitted before Kythera Biopharmaceuticals became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: ATX-101
ATX-101 single doses
Adverse events, laboratory test results, physical examinations
Time frame: 1 - 28 days
Histopathology
Time frame: 1 - 28 Days
The record gives a start of Nov 2008, a primary completion of Mar 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: APIM-containing Peptide ATX-101